-
1.发明公开METHOD FOR TOLERIZING A MAMMALIAN PATIENT TO ADMINISTRATION OF GENE THERAPY VIRUS VECTORS 失效哺乳动物宽容方法PATIENTES与发言基因治疗的病毒载体
公开(公告)号：EP0930896A1
公开(公告)日：1999-07-28
申请号：EP97940869.0
申请日：1997-09-04
发明人： WILSON, James, M. , CHEN, Youhai
CPC分类号： A61K48/00
摘要： A method for tolerizing a mammalian subject to administration of a live virus carrying a gene for delivery to a cell of the subject is disclosed. The method entails administering to the subject a suitable amount of an inactivated virus prior to administration of the live virus. The prior administration of the inactivated virus suppresses anti-virus cytotoxic T cells, permitting longer transgene persistence once the live virus is administered, and permitting effective readministration of live virus.
-
2.发明授权METHOD FOR TOLERIZING A MAMMALIAN PATIENT TO ADMINISTRATION OF GENE THERAPY VIRUS VECTORS 失效METHOD FOR PRODUCING的哺乳动物PATIENTES公差AGAINST DELIVERY基因治疗的病毒载体
公开(公告)号：EP0930896B1
公开(公告)日：2003-01-02
申请号：EP97940869.7
申请日：1997-09-04
发明人： WILSON, James, M. , CHEN, Youhai
CPC分类号： A61K48/00
摘要： A method for tolerizing a mammalian subject to administration of a live virus carrying a gene for delivery to a cell of the subject is disclosed. The method entails administering to the subject a suitable amount of an inactivated virus prior to administration of the live virus. The prior administration of the inactivated virus suppresses anti-virus cytotoxic T cells, permitting longer transgene persistence once the live virus is administered, and permitting effective readministration of live virus.
摘要翻译： 一种耐受哺乳动物受活病毒携带传递的基因的受试者细胞的给药方法是游离缺失盘。 该方法需要向受试者施用灭活病毒的合适量的活病毒的给药之前。 灭活病毒的现有给药禁止抗病毒细胞毒性T细胞，从而允许更长的持久性的转基因一旦活病毒施用，并允许活病毒的再次给药有效。
-
3.发明公开TRAIL: AN INHIBITOR OF AUTOIMMUNE INFLAMMATION AND CELL CYCLE PROGRESSION 审中-公开TRAIL：AUTO免疫性炎症及细胞周期抑制剂
公开(公告)号：EP1223961A1
公开(公告)日：2002-07-24
申请号：EP00967122.3
申请日：2000-09-29
发明人： CHEN, Youhai
CPC分类号： C07K14/70575 , A61K38/00 , A61K48/00
摘要： The present invention provides a method for achieving normal levels of cellular apoptosis in non-transformed cells of a patient by administering to the patient a therapeutically effective amount of purified TRAIL ligand or active fragment thereof. In particular, such method is provided to a patient suffering from an autoimmune disease or condition, such as arthritis, encephalomyelitis or multiple sclerosis or autoimmune inflammation in the CNS. The present invention further provides a method of blocking the activity of an endogenous TRAIL receptor or inhibitor in a patient by administering to the patient a therapeutically effective amount of a purified TRAIL agonist, in an amount sufficient to enhance the patient's level of TRAIL ligand. In particular, such method is provided to enhance ameliorate or restore cellular apoptosis in non-transformed cells of the patient.
-
-
搜索结果
3 条记录 (耗时 0.011 秒)
